CDKN2A and cancer: Two recent studies correlated CDKN2A/MTAP loss as an ICT resistance marker in several pan cancers but were limited by the small number of HPV– HNSC patients (3, 22) and could not evaluate the contributions and interactions of other chromosomal sites or genes to this observation.